The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis
Nonpharmacological therapies with a good tolerability and safety profile are of interest to many patients with allergic rhinitis, as a relevant proportion of them have reservations about guideline-concordant pharmacological therapies due to their local irritations and side effects. Ectoine is a bact...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2021/5562623 |
id |
doaj-255898d659674976bc109910fd686866 |
---|---|
record_format |
Article |
spelling |
doaj-255898d659674976bc109910fd6868662021-06-14T00:17:15ZengHindawi LimitedBioMed Research International2314-61412021-01-01202110.1155/2021/5562623The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic RhinitisAndreas Bilstein0Nina Werkhäuser1Anna Rybachuk2Ralph Mösges3Ursatec GmbHbitop AGBogomolets National Medical UniversityCRI LtdNonpharmacological therapies with a good tolerability and safety profile are of interest to many patients with allergic rhinitis, as a relevant proportion of them have reservations about guideline-concordant pharmacological therapies due to their local irritations and side effects. Ectoine is a bacterial-derived extremolyte with an ability to protect proteins and biological membranes against damage caused by extreme conditions of salinity, drought, irradiation, pH, and temperature. Evidence from preclinical and clinical studies attests its effectiveness in the treatment of several inflammatory diseases, including allergic rhinitis. In this review, we analyzed 14 recent clinical trials investigating ectoine nasal spray in patients with allergic rhinitis and/or conjunctivitis, including sensitive patient groups like children or pregnant women. Some studies investigated monotherapy with ectoine; others investigated combination therapy of ectoine and an antihistamine or a corticosteroid. Analysis of the study results demonstrated that patients with mild-to-moderate symptoms of allergic rhinitis can be successfully treated with ectoine-containing nasal spray. When applied as monotherapy, ectoine exerted noninferior effects compared to first-line therapies such as antihistamines and cromoglicic acid. Using ectoine as an add-on therapy to antihistamines or intranasal glucocorticosteroids accelerated symptom relief by days and improved the level of symptom relief. Importantly, concomitant treatment with ectoine was proven beneficial in a group of difficult-to-treat patients suffering from moderate-to-severe rhinitis symptoms. Taken together, the natural substance ectoine represents a viable alternative for allergic rhinitis and conjunctivitis patients who wish to avoid local reactions and side effects associated with pharmacological therapies.http://dx.doi.org/10.1155/2021/5562623 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andreas Bilstein Nina Werkhäuser Anna Rybachuk Ralph Mösges |
spellingShingle |
Andreas Bilstein Nina Werkhäuser Anna Rybachuk Ralph Mösges The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis BioMed Research International |
author_facet |
Andreas Bilstein Nina Werkhäuser Anna Rybachuk Ralph Mösges |
author_sort |
Andreas Bilstein |
title |
The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis |
title_short |
The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis |
title_full |
The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis |
title_fullStr |
The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis |
title_full_unstemmed |
The Effectiveness of the Bacteria Derived Extremolyte Ectoine for the Treatment of Allergic Rhinitis |
title_sort |
effectiveness of the bacteria derived extremolyte ectoine for the treatment of allergic rhinitis |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6141 |
publishDate |
2021-01-01 |
description |
Nonpharmacological therapies with a good tolerability and safety profile are of interest to many patients with allergic rhinitis, as a relevant proportion of them have reservations about guideline-concordant pharmacological therapies due to their local irritations and side effects. Ectoine is a bacterial-derived extremolyte with an ability to protect proteins and biological membranes against damage caused by extreme conditions of salinity, drought, irradiation, pH, and temperature. Evidence from preclinical and clinical studies attests its effectiveness in the treatment of several inflammatory diseases, including allergic rhinitis. In this review, we analyzed 14 recent clinical trials investigating ectoine nasal spray in patients with allergic rhinitis and/or conjunctivitis, including sensitive patient groups like children or pregnant women. Some studies investigated monotherapy with ectoine; others investigated combination therapy of ectoine and an antihistamine or a corticosteroid. Analysis of the study results demonstrated that patients with mild-to-moderate symptoms of allergic rhinitis can be successfully treated with ectoine-containing nasal spray. When applied as monotherapy, ectoine exerted noninferior effects compared to first-line therapies such as antihistamines and cromoglicic acid. Using ectoine as an add-on therapy to antihistamines or intranasal glucocorticosteroids accelerated symptom relief by days and improved the level of symptom relief. Importantly, concomitant treatment with ectoine was proven beneficial in a group of difficult-to-treat patients suffering from moderate-to-severe rhinitis symptoms. Taken together, the natural substance ectoine represents a viable alternative for allergic rhinitis and conjunctivitis patients who wish to avoid local reactions and side effects associated with pharmacological therapies. |
url |
http://dx.doi.org/10.1155/2021/5562623 |
work_keys_str_mv |
AT andreasbilstein theeffectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis AT ninawerkhauser theeffectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis AT annarybachuk theeffectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis AT ralphmosges theeffectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis AT andreasbilstein effectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis AT ninawerkhauser effectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis AT annarybachuk effectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis AT ralphmosges effectivenessofthebacteriaderivedextremolyteectoineforthetreatmentofallergicrhinitis |
_version_ |
1721378887545389056 |